NCT06648720View on ClinicalTrials.gov

Efficacy and Safety of Shortening Dual Antiplatelet Therapy Duration with IVUS Guidance in PCI Patients

NANot yet recruitingINTERVENTIONAL

Enrollment

3,566

Participants

Timeline

Start Date

March 1, 2025

Primary Completion Date

March 1, 2028

Study Completion Date

March 1, 2029

Conditions

Coronary Arterial Disease (CAD)Percutaneous Coronary Intervention (PCI)Intravascular UltrasoundDual Antiplatelet Therapy

Interventions

DRUG

DAPT de-escalation

Patients in this group will receive DAPT (aspirin and a P2Y12 inhibitor) for 1 month, followed by monotherapy with a P2Y12 inhibitor for the remaining 11 months.

Trial Locations (1)

70000

University Medical Center of Ho Chi Minh City, Ho Chi Minh City

All Listed Sponsors

collaborator

University of Medicine and Pharmacy at Ho Chi Minh City

OTHER

lead

University Medical Center Ho Chi Minh City (UMC)

OTHER

NCT06648720 - Efficacy and Safety of Shortening Dual Antiplatelet Therapy Duration with IVUS Guidance in PCI Patients | Biotech Hunter | Biotech Hunter